Nabi Biopharmaceuticals Announces Special Cash Dividend

Nabi Biopharmaceuticals Announces Special Cash Dividend

ROCKVILLE, Md., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals
(Nasdaq:NABI) announced today that Nabi's Board of Directors declared a
special cash dividend in the aggregate of approximately $31.4 million, $1.108
per share of Nabi common stock. The special cash dividend is payable to
stockholders of record on October 26, 2012 (which was announced previously)
and will be paid on November 8, 2012.As previously disclosed, in connection
with the proposed business combination transaction of Nabi and Biota Holdings
Limited (ASX:BTA:AU), Nabi intends to return to its stockholders in the form
of this special cash dividend Nabi's remaining cash in excess of the $27
million required under the transaction agreement with Biota to be held by Nabi
at the completion of the transaction, after satisfying outstanding
liabilities.

Certain U.S. Federal Income Tax Consequences to U.S. Stockholders of Special
Cash Dividend

The following summary describes certain material U.S. federal income tax
consequences to U.S. holders of Nabi common stock of the special cash dividend
described above. Unless otherwise specifically indicated herein, this summary
addresses the tax consequences only to a beneficial owner of Nabi common stock
that for U.S. income tax purposes is: (1)a citizen or individual resident of
the U.S., (2)a corporation organized in or under the laws of the U.S. or any
state thereof or the District of Columbia, (3)an estate whose income is
subject to U.S. federal income taxation regardless of its source, or (4)any
trust if a U.S. court is able to exercise primary supervision over the
administration of such trust and one or more U.S. persons have the authority
to control all substantial decisions of the trust, or it has a valid election
in place to be treated as a U.S. person (a "U.S. holder"), and, even with
respect to such beneficial owners, this summary does not address special
considerations that may be applicable to certain specific categories of
investors.

Each U.S. holder of Nabi common stock will be treated for U.S. federal income
tax purposes as receiving a distribution from Nabi equal to the amount of cash
received. That distribution should be treated as a dividend to the extent of
Nabi's current and accumulated earnings and profits, if any. To the extent
that the amount distributed exceeds Nabi's earnings and profits, it should be
applied against and reduce the holder's basis for the holder's shares of Nabi
common stock, and, to the extent that it exceeds such basis, it should be
treated as capital gain. Nabi does not expect to have current or accumulated
earnings and profits through the end of 2012. If that is the case, no part of
the distribution should be treated as a dividend. If the holder has held Nabi
shares for more than one year, capital gain recognized by the holder should
qualify as long-term capital gain. Subject to certain exceptions, dividends
and long-term capital gains received by certain non-corporate U.S. holders
during taxable years beginning before January1, 2013 will be taxed at a
maximum federal rate of 15%.

The immediately preceding paragraph assumes that the special cash dividend by
Nabi to its stockholders will be treated for U.S. federal income tax purposes
as a transaction that is separate and distinct from the reverse stock split
and the proposed business combination transaction with Biota. If, contrary to
that assumption, the special cash dividend were integrated for tax purposes
with the reverse stock split and/or the business combination transaction with
Biota, this could affect the calculation of the extent to which the special
cash dividend constitutes a taxable dividend or capital gain.

Each holder of Nabi common stock is urged to consult its own tax advisor
regarding the U.S. federal, state, local, and foreign income and other tax
consequences of the special cash dividend.Furthermore, each holder of Nabi
common stock should review the more detailed discussion of U.S. federal income
tax consequences to U.S. stockholders of the special cash dividend contained
in the section entitled "Certain U.S. Federal Income Tax Consequences to U.S.
Stockholders of Distributions of Cash and Contingent Value Rights" beginning
on page S-41 of the Supplement to the Proxy Statement filed by Nabi with the
Securities and Exchange Commission (the "SEC") on September 25, 2012.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals, headquartered in Rockville, Maryland, is a
biopharmaceutical company that has focused on the development of vaccines
addressing unmet medical needs, including nicotine addiction. Its sole product
currently in development is NicVAX® (Nicotine Conjugate Vaccine), an
innovative and proprietary investigational vaccine for the treatment of
nicotine addiction and prevention of smoking relapse based on patented
technology. For additional information about Nabi Biopharmaceuticals, please
visit www.nabi.com.

Forward-Looking Statements

Statements set forth above that are not strictly historical are
forward-looking statements. You can identify these forward-looking statements
because they involve our expectations, intentions, beliefs, plans,
projections, anticipations, or other characterizations of future events or
circumstances. These forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties that may cause actual
results to differ materially from those in the forward-looking statements as a
result of any number of factors. These factors include, but are not limited
to, risks that are more fully discussed in Nabi's Annual Report on Form 10-K,
as amended, for fiscal year ended December31, 2011, Quarterly Reports on Form
10-Q for the quarters ended March31 and June30, 2012 and definitive proxy
statement for Nabi stockholders special meeting filed with the SEC on
August7, 2012, as supplemented by the supplement dated September25, 2012,
under the captions "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statement" and elsewhere in such documents. We do not
undertake to update any of these forward-looking statements or to announce the
results of any revisions to these forward-looking statements except as
required by law.

CONTACT: Nabi Investor Relations
         301-770-3099
         www.nabi.com
 
Press spacebar to pause and continue. Press esc to stop.